
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7428991/publications.pdf Version: 2024-02-01



DALLI A RUNNID

#	Article	IF	CITATIONS
1	Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation. Journal of Thoracic Oncology, 2022, 17, 214-227.	0.5	26
2	Impact of the Coronavirus Disease 2019 Pandemic on Global Lung Cancer Clinical Trials: Why It Matters to People With Lung Cancer. JTO Clinical and Research Reports, 2022, 3, 100269.	0.6	0
3	International Association for the Study of Lung Cancer (IASLC) Study of the Impact of COVID-19 on International Lung Cancer Clinical Trials. Journal of Thoracic Oncology, 2022, , .	0.5	4
4	Adjuvant Osimertinib in EGFR-Mutant Early-Stage NSCLC: Does HRQoL Influence Decisions?. Clinical Cancer Research, 2022, , OF1-OF2.	3.2	0
5	2020 Innovation-Based Optimism for Lung Cancer Outcomes. Oncologist, 2021, 26, e454-e472.	1.9	17
6	Optimal Therapy for Advanced Non-Small Cell Lung Cancer Without Driver Alterations. JNCI Cancer Spectrum, 2021, 5, pkab014.	1.4	0
7	Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, e191-e204.	1.1	26
8	Guidance on the Clinical Management of Electronic Cigarette or Vaping-Associated Lung Injury. Journal of Thoracic Oncology, 2020, 15, 1727-1737.	0.5	7
9	Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 510.	1.3	3
10	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Journal of Thoracic Oncology, 2020, 15, 709-740.	0.5	205
11	How gradual retirement has allowed me to spend more time with family and being physically active. Clinical Advances in Hematology and Oncology, 2020, 18, 17-18.	0.3	0
12	MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium. Journal of Thoracic Oncology, 2019, 14, 1666-1671.	0.5	115
13	Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience. Journal of Thoracic Oncology, 2019, 14, 876-889.	0.5	141
14	Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 691-700.	0.5	108
15	New Developments in Neoadjuvant Therapy for Lung Cancer. Oncology, 2019, 33, 101-6, 109.	0.4	6
16	Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy. Lung Cancer, 2018, 118, 148-154.	0.9	2
17	Resistance Mechanisms to Targeted Therapies in <i>ROS1</i> + and <i>ALK</i> + Non–small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 3334-3347.	3.2	182
18	Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. Clinical Lung Cancer, 2018, 19, 331-339.	1.1	15

#	Article	IF	CITATIONS
19	Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. Journal of Thoracic Oncology, 2018, 13, 134-138.	0.5	21
20	The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2). Clinical Cancer Research, 2018, 24, 1038-1047.	3.2	154
21	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 1818-1831.	0.5	133
22	The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non–Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. Journal of Thoracic Oncology, 2018, 13, 1717-1726.	0.5	119
23	Broad-Based Molecular Testing for Lung Cancer. JAMA - Journal of the American Medical Association, 2018, 320, 445.	3.8	7
24	Small-cell lung cancer: what we know, what we need to know and the path forward. Nature Reviews Cancer, 2017, 17, 725-737.	12.8	558
25	<i>HER2</i> mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. Cancer, 2017, 123, 4099-4105.	2.0	132
26	Advances in lung cancer. Oncotarget, 2017, 8, 78247-78248.	0.8	2
27	Neoadjuvant combination chemotherapy for unresectable stage III non–small cell lung cancer. Cancer, 2016, 122, 674-675.	2.0	0
28	Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status. Lung Cancer, 2016, 96, 27-32.	0.9	20
29	The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016. Journal of Thoracic Oncology, 2016, 11, 946-963.	0.5	173
30	Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines <i>In Vitro</i> and <i>In Vivo</i> . Molecular Cancer Therapeutics, 2016, 15, 2314-2322.	1.9	81
31	New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet, The, 2016, 388, 1012-1024.	6.3	381
32	Scientific Advances in Lung Cancer 2015. Journal of Thoracic Oncology, 2016, 11, 613-638.	0.5	231
33	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. Journal of Thoracic Oncology, 2016, 11, 453-474.	0.5	156
34	Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. Journal of Thoracic Oncology, 2015, 10, 768-777.	0.5	357
35	Fluorescence In Situ Hybridization, Immunohistochemistry, and Next-Generation Sequencing for Detection of EML4-ALK Rearrangement in Lung Cancer. Oncologist, 2015, 20, 316-322.	1.9	151
36	Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring <scp><i>BRAF</i></scp> mutations in the <scp>L</scp> ung <scp>C</scp> ancer <scp>M</scp> utation <scp>C</scp> onsortium. Cancer, 2015, 121, 448-456.	2.0	102

#	Article	IF	CITATIONS
37	Improving the Care of Patients With Stage IB Non–Small-Cell Lung Cancer: Role of Prognostic Signatures and Use of Cell Cycle Progression Biomarkers. Clinical Lung Cancer, 2015, 16, 245-251.	1.1	4
38	Personalized one-two punches for lung cancer. Cell Research, 2015, 25, 269-270.	5.7	4
39	Adjuvant TKIs in NSCLC: what can we learn from RADIANT?. Nature Reviews Clinical Oncology, 2015, 12, 689-690.	12.5	5
40	Is There Clinical Value to Prognostic Signatures in Early-Stage NSCLC?. Clinical Cancer Research, 2014, 20, 1727-1729.	3.2	4
41	Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2014, 32, 3824-3830.	0.8	244
42	Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA - Journal of the American Medical Association, 2014, 311, 1998.	3.8	1,386
43	Reply to A. Braillon. Journal of Clinical Oncology, 2014, 32, 3575-3575.	0.8	1
44	Recent Clinical Advances in Lung Cancer Management. Journal of Clinical Oncology, 2014, 32, 973-982.	0.8	203
45	Progress in research on screening and genetics in lung cancer. Lancet Respiratory Medicine,the, 2014, 2, 19-21.	5.2	1
46	The Evolution of Tumor Classification: A Role for Genomics?. Cancer Cell, 2013, 24, 693-694.	7.7	8
47	Worldwide Overview of the Current Status of Lung Cancer Diagnosis and Treatment. Archives of Pathology and Laboratory Medicine, 2012, 136, 1478-1481.	1.2	58
48	Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1807-1814.	0.5	585
49	A new generation of EGFR tyrosine-kinase inhibitors in NSCLC. Lancet Oncology, The, 2012, 13, 442-443.	5.1	11
50	Oral Iloprost Improves Endobronchial Dysplasia in Former Smokers. Cancer Prevention Research, 2011, 4, 793-802.	0.7	104
51	Surgery With or Without Preoperative Paclitaxel and Carboplatin in Early-Stage Non–Small-Cell Lung Cancer: Southwest Oncology Group Trial S9900, an Intergroup, Randomized, Phase III Trial. Journal of Clinical Oncology, 2010, 28, 1843-1849.	0.8	206
52	Lessons Learned From the Systematic Evaluation of Cutaneous T-Cell Lymphomas at the National Cancer Institute and the Roadmap for Future Studies. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, S74-S79.	0.2	0
53	Epidermal growth factor receptor immunohistochemistry. Cancer, 2008, 112, 1114-1121.	2.0	69
54	Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study. Journal of Clinical Oncology, 2005, 23, 6838-6845.	0.8	574

#	Article	IF	CITATIONS
55	High prevalence of occult endobronchial malignancy in high risk patients with moderate sputum atypia. Lung Cancer, 2005, 49, 187-191.	0.9	29
56	Early-stage NSCLC: the role of radiotherapy and systemic therapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2004, 2 Suppl 2, S31-40.	2.3	2
57	Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer. Seminars in Oncology, 2002, 29, 87-94.	0.8	51
58	Seminars in oncology. Introduction. Seminars in Oncology, 2002, 29, 1-2.	0.8	0
59	Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?. Journal of Clinical Oncology, 2002, 20, 23S-33S.	0.8	75
60	Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial. Journal of Clinical Oncology, 2001, 19, 3210-3218.	0.8	1,072
61	Chemotherapeutic options in lung cancer. Cancer, 1998, 83, 1740-1750.	2.0	4
62	T-Cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: History and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL). Journal of Cellular Biochemistry, 1996, 63, 12-23.	1.2	56
63	NCI-navy medical oncology branch cell line data base. Journal of Cellular Biochemistry, 1996, 63, 32-91.	1.2	244
64	Growth factors in lung cancer: Possible etiologic role and clinical target. Medical and Pediatric Oncology, 1991, 19, 449-458.	1.0	8